RxDoctor Payments Data

Austin Lunney, MD

Internal Medicine · Temple, TXNPI 1841827268

Payments from drug & device makers

$208in general payments, 2019–2025

Across 15 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$135
  • Inari Medical, Inc.$20
  • Sumitomo Pharma America, Inc.$19
  • GSK$18
  • Pfizer$16

What the payments were for

  • Food & beverage$208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie11$135
Inari Medical, Inc.1$20
Sumitomo Pharma America, Inc.1$19
GSK1$18
Pfizer1$16

How this compares

$208 in reported general payments places this provider in the 40th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$188,729
Medicare patients
507
Services billed
2,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$64,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$48,868
OzempicSemaglutide36$35,746
UbrelvyUbrogepant18$28,393
EliquisApixaban18$20,900
RybelsusSemaglutide15$19,757
FarxigaDapagliflozin Propanediol24$16,892
QuliptaAtogepant11$12,020
LinzessLinaclotide13$11,205
XareltoRivaroxaban16$10,774
JanuviaSitagliptin Phosphate11$7,815
Duloxetine Hcl158$3,606
Levothyroxine Sodium251$2,605
Gabapentin216$2,576
Rosuvastatin Calcium254$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess$135$51,61742 claims
GSKTrelegy Ellipta$18$48,86866 claims
PfizerEliquis$16$20,90018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →